Analytics, not advice. Rankings and scores describe past performance and are not recommendations.

Index Fund

ICICI Prudential Nifty Pharma Index Fund - Direct Plan - IDCW

ICICI Prudential Mutual Fund · Managed by Nishit Patel; Ashwini Bharucha; Venus Ahuja

FundScore
Latest NAV
₹20.5598
as of 07 Aug 2026
AUM
Expense ratio
0.32%
as of 30 Jun 2026
Inception
14 May 2026
FundScore
98/100strong
Rank #31 of 1325 in Index Fund · top 2%

A daily percentile of this fund’s past performance within its SEBI category — analytics, not advice, and not a prediction or recommendation.

Trailing returns
Annualised returns to the latest NAV. Refreshed nightly.
1M
4.50%
3M
10.30%
6M
21.01%
1Y
22.49%
3Y CAGR
19.44%
5Y CAGR
Since incep.
22.05%
Fund details
Fund manager
Nishit Patel; Ashwini Bharucha; Venus Ahuja
Riskometer
Very High Risk
Type
Open Ended
Portfolio turnover
26%
Volatility (3Y)
14.5%
Rating (external)
Investment objective

The objective of the Scheme is to invest in companies whose securities are included in Nifty Pharma Index and subject to tracking errors, to endeavor to achieve the returns of the above index. This would be done by investing in all the stocks comprising the Nifty Pharma Index in the same weightage that they represent in Nifty Pharma Index. However, there is no assurance or guarantee that the investment objective of the scheme shall be achieved.

NAV history
Zoom and pan · ranges from 1M to since-inception.
Rolling returns
Every 30-day step. The true distribution, not cherry-picked.
Rank history
Percentile within category over the last 2 years.
FundScore components
Pro-only breakdown of consistency, recency, and volatility scores.

Upgrade to Pro to see the raw drivers behind this scheme's FundScore label.

Pro
Market-cap distribution
Large / mid / small / micro-cap split of this fund's equity holdings, from its latest look-through portfolio. Shown as a share of classified equity.
Large cap56.5%
Mid cap36.5%
Small cap7.0%
Stock holdings
Latest portfolio disclosure for this scheme. Snapshot as of 30 Jun 2026.
Sun Pharmaceutical Industries Ltd.
equity
21.31%
Divi's Laboratories Ltd.
equity
9.04%
Dr. Reddy's Laboratories Ltd.
equity
8.94%
Cipla Ltd.
equity
8.91%
Laurus Labs Ltd.
equity
6.38%
Lupin Ltd.
equity
6.35%
Torrent Pharmaceuticals Ltd.
equity
5.24%
Aurobindo Pharma Ltd.
equity
4.72%
Glenmark Pharmaceuticals Ltd.
equity
3.59%
Alkem Laboratories Ltd.
equity
3.52%
Biocon Ltd.
equity
3.23%
Mankind Pharma Ltd.
equity
3.11%
Zydus Lifesciences Ltd.
equity
3.01%
IPCA Laboratories Ltd.
equity
2.55%
Gland Pharma Ltd.
equity
2.15%
J.B.Chemicals & Pharmaceuticals Ltd.
equity
2.03%
Wockhardt Ltd.
equity
1.73%
Ajanta Pharma Ltd.
equity
1.56%
Abbott India Ltd.
equity
1.43%
Piramal Pharma Ltd.
equity
1.13%